We read with great interest the recent article published in the Journal of Infection investigating the effectiveness of molnupiravir, nirmatrelvir–ritonavir, and sotrovimab
in preventing hospital admission or death among COVID-19 patients.
1
We noticed that despite the use of broad-spectrum antivirals (e.g. remdesivir), monoclonal
antibodies, corticosteroids, hydroxychloroquine
- Evans A.
- Qi C.
- Adebayo J.O.
- Underwood J.
- Coulson J.
- Bailey R.
- et al.
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on
preventing hospital admission among higher-risk patients with COVID-19 in Wales: a
retrospective cohort study.
J Infect. 2023; https://doi.org/10.1016/j.jinf.2023.02.012
2
being attempted, only limited effectiveness was achieved in reducing mortality, along
with financial and logistical limitations, preventing their widespread use. Hence,
the pertinent question on whether the short-term evidence on the effectiveness of
COVID-19 oral antivirals in reducing risk of mortality and hospitalizations holds
true even in the post-acute phase, especially in a largely vaccinated global population
in an Omicron-dominant setting, remains to be explored.
3
Thus, by examining two cohorts of hospitalized patients from Hong Kong prescribed
with either molnupiravir or nirmatrelvir–ritonavir, this longitudinal study aims to
assess the benefits of both drugs in reducing all-cause mortality in COVID-19 vaccine
recipients compared to non-recipients in an in-patient setting in the post-acute phase
of infection.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.J Infect. 2023; https://doi.org/10.1016/j.jinf.2023.02.012
- A living WHO guideline on drugs for covid-19.BMJ. 2020; 370: m3379
- Long-COVID treatments: why the world is still waiting.Nature. 2022; 608 (PubMed PMID: 35945375. Epub 2022/08/10. eng.): 258-260
- Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.Lancet Healthy Longev. 2022; 3: e491-e500
- Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.Lancet Infect Dis. 2022; 22: 64-72
- Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: a case control study.J Infect. 2022; 85: e140-e144
- Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA. 2 infection: a case-control study.Emerg Microbes Infect. 2022; 11: 2304-2314
- Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA. 2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: a case control study.J Infect. 2022; 5: e140-e144
- Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19).Clin Infect Dis. 2022; 76: e26-e33
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.Lancet. 2022; 400: 1213-1222
Article info
Publication history
Published online: February 21, 2023
Accepted:
February 18,
2023
Footnotes
☆Eric Yuk Fai Wan, Boyuan Wang, and Sukriti Mathur are co-first authors and contributed equally.
Identification
Copyright
© 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
